Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

Core Viewpoint - Servier and IDEAYA Biosciences have entered into an exclusive license agreement for darovasertib, a treatment for uveal melanoma, granting Servier regulatory and commercial rights outside the United States while IDEAYA retains rights in the U.S. [1][7] Company Overview - Servier is an independent international pharmaceutical group focused on delivering transformative therapies and has a strong commitment to oncology, allocating nearly 70% of its R&D budget to this field [10][12] - IDEAYA Biosciences specializes in precision medicine for oncology, focusing on the discovery and development of targeted therapies aligned with genetic drivers of cancer [14] Product Development - Darovasertib is a selective protein kinase C (PKC) inhibitor aimed at treating primary and metastatic uveal melanoma, which is a rare and aggressive form of eye cancer [1][5] - The drug has received Breakthrough Therapy Designation and Fast Track designation from the US FDA, indicating its potential as a significant treatment option [6] Financial Terms of the Agreement - IDEAYA will receive an upfront payment of $210 million, with potential additional payments of up to $320 million based on regulatory and commercial milestones, plus double-digit royalties on net sales outside the U.S. [7][8] Clinical Trials - Darovasertib is currently undergoing multiple global clinical trials, including a Phase 2/3 trial in combination with crizotinib and a Phase 3 trial evaluating it as a monotherapy [4][6] - A global Phase 3 randomized clinical trial is planned for 2026 to assess adjuvant darovasertib in primary uveal melanoma patients [4]